First Eagle Investment Management LLC Takes Position in LifeMD, Inc. (NASDAQ:LFMD)

First Eagle Investment Management LLC acquired a new stake in LifeMD, Inc. (NASDAQ:LFMD - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 50,356 shares of the company's stock, valued at approximately $249,000. First Eagle Investment Management LLC owned approximately 0.12% of LifeMD at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. State Street Corp lifted its position in LifeMD by 20.0% in the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company's stock valued at $6,055,000 after acquiring an additional 192,861 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in LifeMD by 21.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company's stock valued at $4,610,000 after acquiring an additional 165,378 shares in the last quarter. Royce & Associates LP raised its stake in LifeMD by 14.6% during the 3rd quarter. Royce & Associates LP now owns 901,041 shares of the company's stock valued at $4,721,000 after buying an additional 114,710 shares during the last quarter. Geode Capital Management LLC raised its stake in LifeMD by 11.4% during the 3rd quarter. Geode Capital Management LLC now owns 819,233 shares of the company's stock valued at $4,293,000 after buying an additional 83,598 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its stake in LifeMD by 4.8% during the 4th quarter. Los Angeles Capital Management LLC now owns 127,435 shares of the company's stock valued at $631,000 after buying an additional 5,850 shares during the last quarter. 35.52% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the completion of the transaction, the chief executive officer now owns 2,703,715 shares in the company, valued at $14,032,280.85. The trade was a 0.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Jessica Friedeman sold 30,000 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.66, for a total value of $169,800.00. Following the transaction, the chief marketing officer now owns 170,000 shares of the company's stock, valued at $962,200. This trade represents a 15.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 105,000 shares of company stock worth $677,050. Corporate insiders own 15.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LFMD. KeyCorp decreased their target price on shares of LifeMD from $10.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. HC Wainwright boosted their target price on shares of LifeMD from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a report on Tuesday, March 11th. Mizuho began coverage on LifeMD in a report on Wednesday, December 4th. They issued a "neutral" rating and a $7.00 target price on the stock. Finally, Lake Street Capital began coverage on LifeMD in a report on Tuesday, December 10th. They issued a "buy" rating and a $12.00 target price on the stock. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $11.43.

LifeMD Stock Down 1.2 %

NASDAQ:LFMD traded down $0.07 on Thursday, reaching $5.65. 815,756 shares of the company's stock traded hands, compared to its average volume of 1,249,609. The stock has a 50-day simple moving average of $5.70 and a 200-day simple moving average of $5.40. The firm has a market cap of $251.90 million, a PE ratio of -8.83 and a beta of 1.50. LifeMD, Inc. has a 12 month low of $3.99 and a 12 month high of $12.88.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The firm had revenue of $64.26 million for the quarter, compared to analysts' expectations of $57.43 million. On average, equities analysts anticipate that LifeMD, Inc. will post -0.56 earnings per share for the current year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.